Does fibrinolytic therapy prevent hemodynamic decompensation in patients with intermediate-risk pulmonary embolism?
Fibrinolytic therapy prevents hemodynamic decompensation in intermediate-risk pulmonary embolism but significantly increases the risk of major hemorrhage and stroke.
In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.).
Meyer et al. (2014) studied this question.